CSC
APTO

Caldwell Sutter Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Caldwell Sutter Capital’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3 Hold
2
– – ﹤0.01% 886
2025
Q4 		$3 Hold
2
– – ﹤0.01% 871
2025
Q3 		$2 Hold
2
– – ﹤0.01% 867
2025
Q2 		$2 Buy
+2
New +$3 ﹤0.01% 851
2025
Q1 		– Sell
-3
Closed -$21 – 925
2024
Q4 		$21 Hold
3
– – ﹤0.01% 886
2024
Q3 		$38 Hold
3
– – ﹤0.01% 892
2024
Q2 		$70 Hold
3
– – ﹤0.01% 900
2024
Q1 		$153 Hold
3
– – ﹤0.01% 889
2023
Q4 		$234 Hold
3
– – ﹤0.01% 913
2023
Q3 		$258 Hold
3
– – ﹤0.01% 847
2023
Q2 		$427 Buy
+3
New +$621 ﹤0.01% 830

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Caldwell Sutter Capital's APTO Position: Q1 2026 in Review

Caldwell Sutter Capital held its Aptose Biosciences, Inc. (APTO) position steady in Q1 2026 at 2 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Caldwell Sutter Capital first reported a position in APTO in Q2 2023 and has held it in 11 quarters since. The position peaked at $427 in Q2 2023. 4 funds tracked by Wall St. Rank hold APTO as of Q1 2026.

  • Caldwell Sutter Capital held 2 shares of Aptose Biosciences, Inc. worth $3 as of Q1 2026.
  • Caldwell Sutter Capital left its Aptose Biosciences, Inc. share count unchanged in Q1 2026.
  • Aptose Biosciences, Inc. made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q1 2026, its #886 holding.
  • Caldwell Sutter Capital first reported a position in Aptose Biosciences, Inc. in Q2 2023 and has held it in 11 quarters since.
  • Caldwell Sutter Capital's Aptose Biosciences, Inc. position peaked at $427 in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2026.

Based on Caldwell Sutter Capital's 13F filing for Q1 2026, filed 6 May 2026.